Walleye Capital LLC Aclaris Therapeutics, Inc. Transaction History

Walleye Capital LLC

$20.4 Billion
Q1 2025

A detailed history of Walleye Capital LLC transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 311,712 shares of ACRS stock, worth $492,504. This represents 0.0% of its overall portfolio holdings.

Number of Shares

311,712

Previous 718,897 56.64%

Holding current value

$492,504

Previous $1.78 Million 73.29%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$1.53 - $2.6 $622,993 - $1.06 Million	-407,185 Reduced 56.64%	311,712 $476,000
Q4 2024 Feb 13, 2025	BUY	$1.15 - $4.59 $826,731 - $3.3 Million	718,897 New	718,897 $1.78 Million
Q3 2023 Nov 14, 2023	SELL	$6.56 - $10.95 $1.48 Million - $2.47 Million	-225,618 Reduced 66.05%	115,962 $794,000
Q2 2023 Aug 14, 2023	BUY	$7.89 - $10.64 $1.76 Million - $2.38 Million	223,656 Added 189.66%	341,580 $3.54 Million
Q1 2023 May 15, 2023	SELL	$7.07 - $17.95 $2.13 Million - $5.41 Million	-301,160 Reduced 71.86%	117,924 $954,000
Q4 2022 Feb 14, 2023	BUY	$14.33 - $18.37 $2.14 Million - $2.74 Million	149,136 Added 55.25%	419,084 $6.6 Million
Q3 2022 Nov 14, 2022	BUY	$13.07 - $18.22 $3.53 Million - $4.92 Million	269,948 New	269,948 $4.25 Million
Q1 2022 May 16, 2022	SELL	$9.74 - $17.92 $100,721 - $185,310	-10,341 Closed	0 $0
Q4 2021 Mar 03, 2022	BUY	$12.27 - $18.49 $126,884 - $191,205	10,341 New	10,341 $150,000
Q3 2019 Nov 14, 2019	SELL	$0.79 - $2.47 $43,450 - $135,850	-55,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$2.13 - $7.06 $117,150 - $388,300	55,000 New	55,000 $120,000

Others Institutions Holding ACRS

# of Institutions

113

Shares Held

92.4M

Call Options Held

35.4K

Put Options Held

32K

View Full List

About Aclaris Therapeutics, Inc.

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $105M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

More about ACRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.

Account

Walleye Capital LLC Aclaris Therapeutics, Inc. Transaction History